Shares of Solar Pharmaceutical Industries Ltd have been buying and selling within the pink and 0.5% decrease on 10 September after the corporate’s Halol manufacturing facility obtained OAI standing from the USFDA.
In its regulatory submitting, the corporate stated that its manufacturing facility in Halol, Gujarat, was inspected by the US Meals and Drug Administration (USFDA) between 2 June and 13 June 2025. After the inspection was accomplished, the USFDA categorised the ability as “Official Motion Indicated” (OAI) because the FDA discovered that the ability was not correctly compliant with the present Good Manufacturing Practices (CGMP).
Halol stays considered one of Solar Pharma’s key manufacturing vegetation, however since December 2022, the USFDA has positioned it underneath import alert, blocking shipments to the US apart from sure exempted merchandise in scarcity instances.
Earlier, the FDA had issued a warning letter to the Halol facility. Solar Pharma should convey the plant into full compliance with FDA and CGMP requirements earlier than it might probably resume shipments to the US market.
At 12:25 pm, the shares of Solar Pharma have been buying and selling flat at Rs 1,591.70 on NSE.
The way forward for investing is right here!
Unicorn Indicators leverages superior AI expertise to offer you highly effective market predictions and actionable inventory scans. Obtain the app right nowand 10x your buying and selling & investing journey!
